Global epidemiology of vaccine-derived poliovirus 2016-2021: A descriptive analysis and retrospective case-control study.
Epidemiology
Global health
Poliovirus
Vaccination
Vaccine derived poliovirus
Journal
EClinicalMedicine
ISSN: 2589-5370
Titre abrégé: EClinicalMedicine
Pays: England
ID NLM: 101733727
Informations de publication
Date de publication:
Aug 2022
Aug 2022
Historique:
received:
22
02
2022
revised:
23
05
2022
accepted:
23
05
2022
entrez:
5
7
2022
pubmed:
6
7
2022
medline:
6
7
2022
Statut:
epublish
Résumé
Vaccine derived poliovirus (VDPV) remains a major barrier to polio eradication, and recent growing emergences are concerning. This paper presents the global epidemiology of circulating VDPV (cVDPV) by exploring associations between demographic and socioeconomic factors with its recent rise. Data on reported cVDPV cases and isolates between January 1 2016 and June 30 2021 were compiled from EPIWATCH, an open-source observatory for outbreak scanning and analysis, the World Health Organisation (WHO) and ProMed, and analysed descriptively. Reports containing cVDPV case information were included while duplicates and defective links were excluded. Data collection occurred from April 5 2021 to July 16 2021. To identify factors associated with cVDPV, a retrospective case-control study comparing socioeconomic profiles of countries which reported cVDPV with those that did not was undertaken with weighted logistic regression analysis. cVDPV caused by serotype 2 poliovirus was the predominant strain (95%) of 1818 total human cVDPV cases reported. Of 40 countries reporting cVDPV cases or isolates, 22 (55%) had polio vaccination coverages below 80%. Low vaccination coverage (Adjusted OR = 83·41, 95% CI: [5·01, 1387·71], p = 0·0020) was found to be associated with increased odds of reporting cVDPV after adjusting for confounding effects of GDP per capita, female adult literacy rates, maternal mortality rate, and Global Peace Index. Our findings reinforce the importance of maintaining high levels of vaccination, as risk of re-emergence rises when immunity wanes. Interventions to increase vaccination and standards of living in developing countries, coupled with robust surveillance are required if humanity hopes to eradicate polio in the near future. This research was supported by the MRFF 2021 Frontier Health and Medical Research Grant (ID RFRHPI000280), Department of Health, the Australian Government.
Sections du résumé
Background
UNASSIGNED
Vaccine derived poliovirus (VDPV) remains a major barrier to polio eradication, and recent growing emergences are concerning. This paper presents the global epidemiology of circulating VDPV (cVDPV) by exploring associations between demographic and socioeconomic factors with its recent rise.
Methods
UNASSIGNED
Data on reported cVDPV cases and isolates between January 1 2016 and June 30 2021 were compiled from EPIWATCH, an open-source observatory for outbreak scanning and analysis, the World Health Organisation (WHO) and ProMed, and analysed descriptively. Reports containing cVDPV case information were included while duplicates and defective links were excluded. Data collection occurred from April 5 2021 to July 16 2021. To identify factors associated with cVDPV, a retrospective case-control study comparing socioeconomic profiles of countries which reported cVDPV with those that did not was undertaken with weighted logistic regression analysis.
Findings
UNASSIGNED
cVDPV caused by serotype 2 poliovirus was the predominant strain (95%) of 1818 total human cVDPV cases reported. Of 40 countries reporting cVDPV cases or isolates, 22 (55%) had polio vaccination coverages below 80%. Low vaccination coverage (Adjusted OR = 83·41, 95% CI: [5·01, 1387·71], p = 0·0020) was found to be associated with increased odds of reporting cVDPV after adjusting for confounding effects of GDP per capita, female adult literacy rates, maternal mortality rate, and Global Peace Index.
Interpretation
UNASSIGNED
Our findings reinforce the importance of maintaining high levels of vaccination, as risk of re-emergence rises when immunity wanes. Interventions to increase vaccination and standards of living in developing countries, coupled with robust surveillance are required if humanity hopes to eradicate polio in the near future.
Funding
UNASSIGNED
This research was supported by the MRFF 2021 Frontier Health and Medical Research Grant (ID RFRHPI000280), Department of Health, the Australian Government.
Identifiants
pubmed: 35784443
doi: 10.1016/j.eclinm.2022.101508
pii: S2589-5370(22)00238-3
pmc: PMC9240990
doi:
Types de publication
Journal Article
Langues
eng
Pagination
101508Informations de copyright
© 2022 The Authors.
Déclaration de conflit d'intérêts
All authors declare no competing interests.
Références
Vaccine. 2017 Sep 25;35(40):5418-5425
pubmed: 28111147
BMC Public Health. 2010 Dec 03;10 Suppl 1:S5
pubmed: 21143827
Vaccine. 2017 Nov 7;35(47):6438-6443
pubmed: 29031691
Virol J. 2007 Jul 10;4:70
pubmed: 17623069
J Infect Dis. 2014 Nov 1;210 Suppl 1:S475-84
pubmed: 25316870
Expert Rev Vaccines. 2016 Jun;15(6):693-708
pubmed: 26751187
BMC Infect Dis. 2014 Jan 29;14:45
pubmed: 24472313
Wkly Epidemiol Rec. 2014 Feb 28;89(9):73-92
pubmed: 24707513
Hum Vaccin Immunother. 2012 Feb;8(2):184-8
pubmed: 22426372
BMJ Open. 2017 Mar 10;7(3):e013853
pubmed: 28283489
Vaccine. 2019 Jun 19;37(28):3694-3703
pubmed: 31155417
Sci Rep. 2017 Dec 12;7(1):17362
pubmed: 29234135
Confl Health. 2019 Jan 29;13:2
pubmed: 31568540
NPJ Vaccines. 2022 Feb 11;7(1):19
pubmed: 35149714
Lancet Infect Dis. 2019 Feb;19(2):140
pubmed: 31876508
J Med Virol. 2021 Jan;93(1):141-143
pubmed: 32603503
Science. 2002 Apr 12;296(5566):356-9
pubmed: 11896235
BMC Public Health. 2016 Sep 13;16:968
pubmed: 27618851
Surgery. 2003 May;133(5):588
pubmed: 12773989
Science. 2014 May 23;344(6186):851-5
pubmed: 24855260
BMC Health Serv Res. 2017 Sep 26;17(1):681
pubmed: 28950899